About the Company
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological Research
Employees
2600
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $INCY News
Incyte to acquire San Diego pharma firm in $750 million deal
Incyte says the firm it is acquiring has new drug candidates representing multibillion-dollar revenue opportunities.
Incyte’s Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip
Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Incyte (INCY – Research Report), reducing the price target to ...
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening ...
Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Incyte Corporation's underperformance belies its solid growth, profitability, and increased cash position. Click here for my ...
Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M
Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 ...
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Incyte to acquire Escient Pharmaceuticals and its pipeline of first-in-class oral MRGPR antagonists with the potential to ...
Loading the latest forecasts...